Interim Report 2010.01.01 - 2010.03.31

Net sales increased by 45 percent during the first quarter, with revenue unchanged vs. last year

• Net sales amounted to 15.9 million SEK (15.9). • EBIT amounted to 3.2 million SEK (2.2). • Profit after tax amounted to 2.4 million SEK (2.1). • Earnings per share amounted to 0.26 SEK (0.23). • Cash flow amounted to 1.7 million SEK (3.4). • Probi’s immune defense supplement to be launched in South Africa. • Positive result with Probi’s probiotics in clinical study on subjects with IBS, in India. • Royalty proceeds from ProViva were 8 percent higher than the first quarter of 2009. • Probi forecasts EBIT and cash flow to be positive in 2010. Key events after the period’s end: • Probi establishes Scientific Advisory Board. CEO’s COMMENTS: ”The 45 percent increase in EBIT in Q1 2010 demonstrates the strength of our business model. Net sales were unchanged compared to the first quarter of 2009, but it is noteworthy that proceeds from ProViva were the highest since launch in 1994. To further reinforce Probi’s leadership in probiotic research, we are now establishing a Scientific Advisory Board with world leading scientists who are leaders in fields relevant to probiotics,” says Michael Oredsson, CEO of Probi. FOR FURTHER INFORMATION, CONTACT: Michael Oredsson, CEO Probi, phone: +46 46 286 89 23, mobile: +46 707 18 89 30, e-mail: michael.oredsson@probi.se. Distributed 2010-04-22, 9.15 (CET)